Inventiva S.A. (NASDAQ:IVA - Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 77,700 shares, a growth of 34.9% from the March 31st total of 57,600 shares. Based on an average daily volume of 39,500 shares, the short-interest ratio is currently 2.0 days.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Lifesci Capital reissued an "outperform" rating on shares of Inventiva in a research note on Friday, January 5th. Canaccord Genuity Group upped their target price on shares of Inventiva from $12.00 to $20.00 and gave the company a "buy" rating in a research report on Monday, April 8th. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Inventiva in a research report on Monday, April 1st. Finally, Stifel Nicolaus cut their price objective on shares of Inventiva from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Friday, February 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $17.00.
Check Out Our Latest Stock Report on IVA
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Inventiva stock. Commonwealth Equity Services LLC raised its holdings in Inventiva S.A. (NASDAQ:IVA - Free Report) by 20.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,435 shares of the company's stock after acquiring an additional 4,155 shares during the period. Commonwealth Equity Services LLC's holdings in Inventiva were worth $103,000 as of its most recent filing with the Securities and Exchange Commission. 19.06% of the stock is owned by institutional investors and hedge funds.
Inventiva Price Performance
Shares of Inventiva stock traded up $0.09 during trading on Friday, hitting $3.25. 24,741 shares of the company were exchanged, compared to its average volume of 24,361. The firm's fifty day moving average price is $3.63 and its 200 day moving average price is $3.90. Inventiva has a 1-year low of $2.40 and a 1-year high of $5.05.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Read More
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
